Brevan Howard Capital Management’s Vor Biopharma VOR Stock Holding History

Brevan Howard Capital Management’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$753K	Buy	+42,217	New	+$595K	0.01%	1065

Other funds holding VOR

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Brevan Howard Capital Management's VOR Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Vor Biopharma (VOR) in Q1 2026: 42,217 shares worth $753K. The stake represents 0.01% of the portfolio and ranks #1065 among its holdings.

80 funds tracked by Wall St. Rank hold VOR as of Q1 2026.

Brevan Howard Capital Management held 42,217 shares of Vor Biopharma worth $753K as of Q1 2026.
Vor Biopharma was a new Brevan Howard Capital Management position in Q1 2026.
Vor Biopharma made up 0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1065 holding.
80 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.